European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
Jul 26, 2024
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."
https://www.cnbc.com/2024/07/26/biogen-eisai-alzheimers-drug-leqembi-rejected-by-european-regulator.html
Respond, make new discussions, see other discussions and customize your news...

To add this website to your home screen:

1. Tap tutorialsPoint

2. Select 'Add to Home screen' or 'Install app'.

3. Follow the on-scrren instructions.

Feedback
FAQ
Privacy Policy
Terms of Service